日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

纳武利尤单抗联合AVD方案作为经典型霍奇金淋巴瘤患者的一线治疗:来自美国20个中心的真实世界分析

Quinquenel, Anne; Aurran-Schleinitz, Thérèse; Clavert, Aline; Cymbalista, Florence; Dartigeas, Caroline; Davi, Frédéric; de Guibert, Sophie; Delmer, Alain; Dilhuydy, Marie-Sarah; Feugier, Pierre; Fornecker, Luc-Matthieu; Ghez, David; Guieze, Romain; Laribi, Kamel; Leblond, Véronique; Leprêtre, Stéphane; Letestu, Rémi; Lévy, Vincent; Nguyen-Khac, Florence; Michallet, Anne-Sophie; Tomowiak, Cécile; Tournilhac, Olivier; Ysebaert, Loïc; Troussard, Xavier; Bock, Allison M; Hao, Peirong; Xu, Yizhe; Luttwak, Efrat; Thiruvengadam, Swetha Kambhampati; Sekaran, Kanithra; Sano, Dahlia; Vaughn, John; Sharp, John; Major, Ajay; Patel, Vrutti; Smilnak, Gordon; Araujo, Nicole; Mynam, Ritwick; Reef, Daniel; Palmeri, Marisa; Gerber, Drew; Abhyankar, Anuja; Baek, Grace; Falade, Ayo; Iqbal, Madiha; Hu, Boyu; Geethakumari, Praveen Ramakrishnan; Durani, Urshila; Di, Mengyang; Niu, Alex; Cherng, Hua‐Jay J; Rhodes, Joanna M; Grover, Natalie; Pophali, Priyanka; Feldman, Tatyana; Shanmugasundaram, Krithika; Svoboda, Jakub; Voorhees, Timothy; Diefenbach, Catherine; Karimi, Yasmin; Karmali, Reem; Herrera, Alex F; Torka, Pallawi; Epperla, Narendranath

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group

在既往未接受治疗的中危慢性淋巴细胞白血病患者中,以可测量的残余病灶为指导,比较伊布替尼联合维奈克拉与FCR方案的疗效:一项来自FILO组的II期随机试验(ERADIC)。

Quinquenel, Anne; Letestu, Rémi; Le Garff-Tavernier, Magali; Morisset, Stéphane; Subtil, Fabien; Aurran, Thérèse; Laribi, Kamel; Cymbalista, Florence; Lévy, Vincent; Simon, Laurence; Roos-Weil, Damien; Leblond, Véronique; Dilhuydy, Marie-Sarah; Tomowiak, Cécile; Dartigeas, Caroline; Guièze, Romain; Tournilhac, Olivier; Ferrant, Emmanuelle; de Guibert, Sophie; Feugier, Pierre; Merabet, Fatiha; Leprêtre, Stéphane; Carassou, Philippe; Gay, Julie; Hivert, Bénédicte; Fornecker, Luc-Matthieu; Dupuis, Jehan; Molina, Lysiane; Villemagne, Bruno; Cartron, Guillaume; Drenou, Bernard; Mahé, Beatrice; Benbrahim, Omar; Cahu, Xavier; Portois, Christelle; Ysebaert, Loïc; Nguyen-Khac, Florence; Dahmani, Abdelmalek; Quiney, Claire; Rouillé, Valérie; Delmer, Alain; Michallet, Anne-Sophie

Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness

抗HLA I类IgG亚类在输血无效中影响血小板活化机制

Couvidou, Adèle; Wald, Mathieu; Angénieux, Catherine; Pires-Marafon, Juliana; Apithy, Marie-Joëlle; Humbrecht, Catherine; Fornecker, Luc-Matthieu; Congy-Jolivet, Nicolas; Dupuis, Arnaud; Rollin, Jérôme; Maître, Blandine

Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials

来自LYSA研究组的混合临床试验和真实世界数据的合成对照组,适用于80岁以上未经治疗的弥漫性大B细胞淋巴瘤患者:一项切实可行的创新临床试验策略

Letailleur, Valentin; Chaillol, Isabelle; Cherblanc, Fanny; Ghesquières, Hervé; Peyrade, Frédéric; Guidez, Stéphanie; Bijou, Fontanet; Sesques, Pierre; Rossi, Cédric; Fornecker, Luc-Matthieu; Fouillet, Ludovic; Carras, Sylvain; Chartier, Loïc; Belot, Aurélien; Oberic, Lucie; Jardin, Fabrice; Tessoulin, Benoit

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study

tafasitamab联合来那度胺治疗复发或难治性弥漫性大B细胞淋巴瘤的临床获益:来自EarlyMIND研究的真实世界数据

Brisou, Gabriel; Paillassa, Jérôme; Bernard, Sophie; Tournilhac, Olivier; Fornecker, Luc-Matthieu; Maloisel, Frédéric; Gastaud, Lauris; Durot, Eric; Tempescul, Adrian; Braun, Thorsten; Ivanov, Vadim; Cherel, Brieuc; Serrier, Caroline; Delage, Jeremy; El Yamani, Abderrazak; Delapierre, Baptiste; Lebras, Laure; Lestang, Elsa; Villesuzanne, Camille; Agape, Philippe; Escure, Guillaume; Fouillet, Ludovic; Nicol, Christophe; Olivier, Gaëlle; Levy, Anthony; Le Bris, Anne-Sophie; Cassuto, Ophélie; Jacquemelle, Laura; Haioun, Corinne; Herbaux, Charles

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

4个疗程后的中期PET检查可预测组织分子学确诊的原发性纵隔B细胞淋巴瘤的预后

Camus, Vincent; Molina, Thierry; Desmots, Fabienne; Blanc-Durand, Paul; Kanoun, Salim; Moslemi, Amine; Ruminy, Philippe; Le Gouill, Steven; Ghesquières, Hervé; Oberic, Lucie; Morschhauser, Franck; Tilly, Hervé; Ribrag, Vincent; Houot, Roch; Thieblemont, Catherine; Maisonneuve, Hervé; Claves, Fabien; Bouabdallah, Krimo; Haioun, Corinne; Damaj, Gandhi Laurent; Fornecker, Luc-Matthieu; Noel, Robin; Feugier, Pierre; Sibon, David; Cartron, Guillaume; Bonnet, Christophe; Bernard, Wivine; Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline; Jais, Jean-Philippe; Brière, Josette; Rossi, Cedric; Elsensohn, Mad-Hélénie; Chartier, Loïc; Itti, Emmanuel; Jardin, Fabrice; Fest, Thierry

Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders

基于人工智能的流式细胞术在B细胞慢性淋巴增殖性疾病诊断中的应用

Mauvieux, Laurent; Herbrecht, Raoul; Eischen, Alice; Galoisy, Anne-Cécile; Rolland, Delphine; Gervais, Carine; Mayeur-Rousse, Caroline; Hueber-Bonnot, Sarah; Nicolae, Alina; Fornecker, Luc-Matthieu; Goetsch, Thibaut; Severac, François; Bizoï, Razvan; Fabacher, Thibaut; Miguet, Laurent

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

阿特珠单抗、奥妥珠单抗和维奈托克治疗复发/难治性B细胞非霍奇金淋巴瘤患者:LYSA研究组II期试验的最终分析

Herbaux, Charles; Bachy, Emmanuel; Bouabdallah, Reda; Guidez, Stéphanie; Casasnovas, Olivier; Feugier, Pierre; Damaj, Gandhi; Tilly, Hervé; Ysebaert, Loïc; Le Gouill, Steven; Morineau, Nadine; Gyan, Emmanuel; Gressin, Rémy; Houot, Roch; Cheminant, Morgane; Morschhauser, Franck; Thieblemont, Catherine; Haioun, Corinne; Nicolas-Virelizier, Emmanuelle; Fornecker, Luc-Matthieu; Daguindau, Nicolas; Cartron, Guillaume

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

通过非侵入性基因组分析定义的霍奇金淋巴瘤不同亚型

Stefan K Alig # ,Mohammad Shahrokh Esfahani # ,Andrea Garofalo # ,Michael Yu Li # ,Cédric Rossi ,Tim Flerlage ,Jamie E Flerlage ,Ragini Adams ,Michael S Binkley ,Navika Shukla ,Michael C Jin ,Mari Olsen ,Adèle Telenius ,Jurik A Mutter ,Joseph G Schroers-Martin ,Brian J Sworder ,Shinya Rai ,Daniel A King ,Andre Schultz ,Jan Bögeholz ,Shengqin Su ,Karan R Kathuria ,Chih Long Liu ,Xiaoman Kang ,Maya J Strohband ,Deanna Langfitt ,Kristine Faye Pobre-Piza ,Sherri Surman ,Feng Tian ,Valeria Spina ,Thomas Tousseyn ,Lieselot Buedts ,Richard Hoppe ,Yasodha Natkunam ,Luc-Matthieu Fornecker ,Sharon M Castellino ,Ranjana Advani ,Davide Rossi ,Ryan Lynch ,Hervé Ghesquières ,Olivier Casasnovas ,David M Kurtz ,Lianna J Marks ,Michael P Link ,Marc André ,Peter Vandenberghe ,Christian Steidl ,Maximilian Diehn ,Ash A Alizadeh

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group

RiBVD II期试验的长期分析揭示了TP53突变和低白蛋白血症对老年套细胞淋巴瘤患者的不利影响;对于LYSA组

Carras, Sylvain; Torroja, Alexia; Emadali, Anouk; Montaut, Emilie; Daguindau, Nicolas; Tempescul, Adrian; Moreau, Anne; Tchernonog, Emmanuelle; Schmitt, Anna; Houot, Roch; Dartigeas, Caroline; Barbieux, Sarah; Corm, Selim; Banos, Anne; Fouillet, Ludovic; Dupuis, Jehan; Macro, Margaret; Fleury, Joel; Jardin, Fabrice; Sarkozy, Clementine; Damaj, Ghandi; Feugier, Pierre; Fornecker, Luc Matthieu; Chabrot, Cecile; Dorvaux, Veronique; Bouabdallah, Krimo; Amorim, Sandy; Garidi, Reda; Voillat, Laurent; Joly, Bertrand; Morineau, Nadine; Moles, Marie Pierre; Zerazhi, Hacene; Fontan, Jean; Arkam, Yazid; Alexis, Magda; Delwail, Vincent; Vilque, Jean Pierre; Ysebaert, Loic; Burroni, Barbara; Callanan, Mary; Le Gouill, Steven; Gressin, Rémy